Myriad Genetics and Sophia Genetics have announced a collaboration to advance a prostate cancer-specific genomic instability score, known as PrGIS, to support precision oncology approaches with AstraZeneca.
PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and
As part of the collaboration, Sophia Genetics will incorporate PrGIS into a companion diagnostic that it will make available to patients around the world. Financial and other details of the deal were not disclosed.
“PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies,” Lou Welebob, senior VP of companion diagnostics at Myriad, said in a statement.
Myriad developed PrGIS to support HRD as a biomarker in prostate cancer. The score will be produced by Myriad’s MyChoice CDx test, which is currently available as a companion diagnostic in ovarian cancer and is being advanced for prostate cancer.
Myriad noted it plans to present PrGIS characterization and validation data in research coauthored with AstraZeneca at the European Society for Medical Oncology (ESMO) Congress 2026 in late October.